• In June 2026, Twist Bioscience filed an omnibus shelf registration covering common and preferred stock, debt, warrants, and units, and separately registered a US$200,000,000 at-the-market follow-on equity offering of its common shares.
• At the same time, Twist drew fresh attention from Osterweis Opportunity Fund for its role in liquid biopsy and as an outsourced wet lab for AI genomics, underscoring how its synthetic DNA platform is being used at the intersection of genomics and artificial intelligence.
• We will now examine how Twist’s expanded financing flexibility and growing role in AI-driven genomics research may influence its existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Twist Bioscience Investment Narrative Recap

To own Twist Bioscience, you need to believe that its synthetic DNA platform can become an essential toolset for NGS, SynBio, and AI-enabled genomics, and that it can eventually narrow sizeable losses toward breakeven. The new shelf and US$200,000,000 at the market program expand financing flexibility, which is relevant because ongoing losses and heavy R&D spend keep future dilution risk front and center as the key short term concern.

Against that backdrop, the fresh attention from Osterweis Opportunity Fund is particularly relevant, because it highlights Twist’s role in liquid biopsy and as an outsourced wet lab for AI genomics. This reinforces one of the core growth catalysts behind the story: deeper integration of Twist’s DNA and library prep products into high value clinical and AI driven research workflows that can support revenue expansion and help absorb the increased capital access signaled by the new filings.

Yet despite this progress, the risk that continued losses could still force more equity issuance is something investors should be aware of...

Twist Bioscience's narrative projects $660.4 million revenue and $125.4 million earnings by 2029.

Uncover how Twist Bioscience's forecasts yield a $71.10 fair value, a 19% downside to its current price.

Exploring Other Perspectives

Some of the lowest analysts paint a much harsher picture than consensus, assuming about 15 percent annual revenue growth and no profits by 2029, so as you weigh Twist’s new financing and AI genomics exposure, it is worth comparing their more pessimistic view to your own expectations.

Explore 3 other fair value estimates on Twist Bioscience - why the stock might be worth as much as 55% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Twist Bioscience research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Twist Bioscience's overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.